Zealand, Roche Start Phase 2 Obesity Combination Trial

The ZYNERGY study tests petrelintide alongside Roche's enicepatide in adults with obesity or overweight.

Updated on Nov. 18, 2026 in Weight Loss

Zealand, Roche Start Phase 2 Obesity Combination Trial

Zealand Pharma initiated the Phase 2 ZYNERGY trial of petrelintide co-administered with enicepatide, a Roche-sponsored and conducted study announced November 18, 2026. The randomized, double-blind, placebo-controlled trial compares the combination against placebo and each drug given alone.

Why it matters

The trial tests whether pairing a long-acting amylin analog with a GLP-1/GIP receptor dual agonist can address obesity more effectively than either drug alone. Results will help determine dose selection for a potential Phase 3 program.

The trial enrolls adults with obesity or overweight plus at least one weight-related comorbidity and tests three dose regimens of the combination. Efficacy and safety outcomes remain unknown until the week 40 primary endpoint and week 50 follow-up are complete.

The players

Zealand Pharma A/S

Zealand Pharma is a Danish biopharmaceutical company headquartered in Copenhagen that develops peptide-based therapies for metabolic diseases.

Roche

Roche is a Swiss multinational pharmaceutical and diagnostics company and a leading developer of obesity and metabolic medicines.

The details

Participants receive once-weekly co-administration of petrelintide and enicepatide after a screening period and dose escalation, with maintenance continuing to week 40. The companies signed an exclusive collaboration and licensing agreement in 2025 to co-develop and co-commercialize petrelintide.

Timeline

  1. 2025: Zealand Pharma and Roche signed the petrelintide collaboration agreement.

  2. November 18, 2026: Zealand Pharma announced the ZYNERGY trial initiation.

  3. Week 40: Primary endpoint measured and maintenance period ends.

  4. Week 50: Follow-up period ends.

Big Picture

The trial builds on the incretin drug class established by GLP-1-based obesity medicines, adding an amylin analog to explore a second mechanism. It reflects a broader industry effort to move beyond single-pathway weight-loss drugs.

This trial is at an early research stage and does not change current access to any treatment. Its results will determine whether the combination advances toward Phase 3 testing and eventual availability.

The takeaway

Obesity drug research is increasingly testing combinations of mechanisms rather than single agents. Readers should watch for week 40 primary endpoint results before drawing conclusions about efficacy.

What happens next

The primary endpoint is measured at week 40 and follow-up concludes at week 50 of the ZYNERGY trial.

Further reading

Explore more on Weight Loss research and treatment developments.

More information

Review the ZYNERGY trial registry entry on ClinicalTrials.gov for study design details.

Source note: This article includes information reported by The Manila times.